This public-private partnership seeks to develop new ways of identifying and validating promising biological targets for diagnostics and drug development.
Scientists can distinguish between highly similar cell types using cutting-edge laboratory procedures. Using such techniques, IRP researchers have identified a particular variety of cell in a specific stage of its life cycle as a primary culprit behind the autoimmune disease known as lupus.
Known as the “disease with a thousand faces,” systemic lupus erythematosus is a lifelong autoimmune disease with a wide range of symptoms and signs—fatigue, fever, joint pain, facial rash and skin lesions, shortness of breath, and more. It may develop suddenly or slowly and be mild or severe, with people affected going through periods of flare up and remission of their symptoms.
Researchers have identified a potential treatment to reduce the risk of cardiovascular disease in people with systemic lupus erythematosus (SLE), a chronic autoimmune disease.
A type of skin cell called a dermal fibroblast can make an antimicrobial compound called cathelicidin in response to infection by acne-causing bacteria.
Human skin is home to diverse ecosystems including bacteria, viruses, and fungi. These microbial communities comprise hundreds of species and are collectively known as the skin microbiome.
Video of a Facebook Live discussion on lupus research, treatment, and care, moderated by Rev. Cheryl Ward and featuring experts in the field.
Dr. Kaplan has studied a number of autoimmune diseases, from rheumatoid arthritis to vasculitis, but most of her efforts have been focused on what she calls “the poster child” for autoimmune diseases: systemic lupus erythematosus (SLE), more commonly referred to as ‘lupus.’